Health Care·Biotechnology·$6.1B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.46 | N/A | -287.27% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-1.46 | N/A | -287.27% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Overall, management expressed concerns about the current financial performance but highlighted strategic initiatives aimed at recovery. They did not provide specific guidance for the upcoming quarters.
Management acknowledged the challenges faced during the quarter.
They emphasized ongoing efforts to improve operational efficiency.
Future plans include a focus on key therapeutic areas.
Despite missing EPS expectations significantly, Centessa Pharmaceuticals' stock surged by over 44%. This increase may be attributed to investor optimism about the company's strategic initiatives and potential future developments, even in light of the disappointing earnings report.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
NIKE INC Class B
Mar 31, 2026